Incidence and outcome of BCR‐ABL mutated chronic myeloid leukemia patients who failed to tyrosine kinase inhibitors

Autor: Gabriel Etienne, Stéphanie Dulucq, Françoise Huguet, Anna Schmitt, Axelle Lascaux, Sandrine Hayette, Marie‐Pierre Fort, Pierre Sujobert, Fontanet Bijou, Stéphane Morisset, Suzanne Tavitian, Audrey Bidet, Beatrice Turcq, Fanny Robbesyn, Claudine Chollet, Francis Belloc, Françoise Durrieu, François‐Xavier Mahon, Franck E. Nicolini

Publikováno v: Cancer Medicine, Vol 8, Iss 11, Pp 5173-5182 (2019)

Abstract Purpose To assess the incidence of BCR‐ABL kinase domain (KD) mutation detection and its prognostic significance in chronic phase chronic myeloid leukemia (CP‐CML) patients treated with tyrosine kinase inhibitors (TKIs). Patients and Met

Externí odkaz: https://doaj.org/article/6e01c6179d7a4668b2becca6369a87e0

A single nucleotide polymorphism in cBIM is associated with a slower achievement of major molecular response in chronic myeloid leukaemia treated with imatinib.

Autor: Vanessa Augis, Kelly Airiau, Marina Josselin, Béatrice Turcq, François-Xavier Mahon, Francis Belloc

Publikováno v: PLoS ONE, Vol 8, Iss 11, p e78582 (2013)

BIM is essential for the response to tyrosine-kinase inhibitors (TKI) in chronic myeloid leukaemia (CML) patients. Recently, a deletion polymorphism in intron 2 of the BIM gene was demonstrated to confer an intrinsic TKI resistance in Asian patients.

Externí odkaz: https://doaj.org/article/1913005b509b4f78b630d4f9a2c6f7bd

Supplementary Figure 1 from Evidence that Resistance to Nilotinib May Be Due to BCR-ABL, Pgp, or Src Kinase Overexpression

Autor: Jean-Max Pasquet, Serge Roche, Gabriel Etienne, Cédric Leroy, Paul W. Manley, Coralie Belanger, Franck Nicolini, Béatrice Turcq, Francis Belloc, Valérie Lagarde, Sandrine Hayette, François-Xavier Mahon

Supplementary Figure 1 from Evidence that Resistance to Nilotinib May Be Due to BCR-ABL, Pgp, or Src Kinase Overexpression

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15ab1f3bff6bbe20196d7882c1f25cc6
https://doi.org/10.1158/0008-5472.22375485.v1

Incidence and outcome of BCR‐ABL mutated chronic myeloid leukemia patients who failed to tyrosine kinase inhibitors

Autor: Sandrine Hayette, Anna Schmitt, Françoise Huguet, Marie-Pierre Fort, Gabriel Etienne, Francois-Xavier Mahon, Béatrice Turcq, Fanny Robbesyn, Pierre Sujobert, Suzanne Tavitian, Claudine Chollet, Stephane Morisset, Francis Belloc, Axelle Lascaux, Franck E. Nicolini, Stéphanie Dulucq, Françoise Durrieu, Fontanet Bijou, Audrey Bidet

Publikováno v: Cancer Medicine, Vol 8, Iss 11, Pp 5173-5182 (2019)
Cancer Medicine
Cancer Medicine, Wiley, 2019, 8 (11), pp.5173-5182. ⟨10.1002/cam4.2410⟩
Cancer Medicine, 2019, 8 (11), pp.5173-5182. ⟨10.1002/cam4.2410⟩

International audience; PurposeTo assess the incidence of BCR‐ABL kinase domain (KD) mutation detection and its prognostic significance in chronic phase chronic myeloid leukemia (CP‐CML) patients treated with tyrosine kinase inhibitors (TKIs).Pat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::26fb3180088663f8208c8b506fc5c9d0
https://doaj.org/article/6e01c6179d7a4668b2becca6369a87e0

Dasatinib-Loaded Erythrocytes Trigger Apoptosis in Untreated Chronic Myelogenous Leukemic Cells: A Cellular Reservoir Participating in Dasatinib Efficiency

Autor: Jean-Philippe Vial, Elodie Laharanne, Stéphane Bouchet, Béatrice Turcq, Francis Belloc, Gabriel Etienne, Francois-Xavier Mahon, Kelly Airiau

Publikováno v: HemaSphere, Vol 2, Iss 3 (2018)
HemaSphere

Supplemental Digital Content is available in the text
Dasatinib is an ABL1 tyrosine kinase inhibitor (TKI) with a short in vivo plasmatic half-life but with good efficiency, which is not fully understood. We investigated the possibility that cir

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7054880ca14332800b04e13bb98ffe94
http://journals.lww.com/10.1097/HS9.0000000000000041